Medical Bulletin 23/December/2021
Here are Top Medical stories of the dayFaster transmission of the Omicron virus and why third dose might be needed A team of researchers from Hong Kong University (HKU) has given an explanation on why the Omicron variant of the SARS-CoV-2 virus transmits faster. They reported that the new variant multiplies 70 times faster in the bronchi than the original SARS-CoV-2 and the Delta...
Here are Top Medical stories of the day
Faster transmission of the Omicron virus and why third dose might be needed
A team of researchers from Hong Kong University (HKU) has given an explanation on why the Omicron variant of the SARS-CoV-2 virus transmits faster. They reported that the new variant multiplies 70 times faster in the bronchi than the original SARS-CoV-2 and the Delta virus.
According to the authors, these are the first findings on how the Omicron variant (B11529) infects the respiratory tract. Also, they found that Omicron infection in the lung is significantly lower than the original virus, which may be an indicator of lower disease severity.
For more details, check out the full story on the link below:
Study Explains Faster Transmission Of The Omicron Virus And Why Third Dose Might Be Needed
Irregular menses may indicate underlying CVD and diabetes
Irregular menses may signal underlying cardiovascular disease and diabetes, according to a recent study published in Clinical endocrinology.
Menstrual cycle regularity underpins the diagnosis of polycystic ovary syndrome (PCOS), which is linked to adverse cardio-metabolic profile. However, links between menstrual disorders and metabolic conditions are often under-appreciated and not considered when assessing cardio-metabolic risk in women. A group of researchers aimed to assess the risk of diabetes and heart disease in women with irregular menstrual cycles and those whose cycles were regular.
For more details, check out the full story on the link below:
Irregular Menses May Indicate Underlying CVD And Diabetes: Study
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ / XELJANZ XR (tofacitinib) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
"We are proud to offer XELJANZ, a treatment option for ankylosing spondylitis that does not require an injection or an infusion, to treat this debilitating and chronic immuno-inflammatory disease," said Mike Gladstone, Global President, Inflammation & Immunology, Pfizer. "This regulatory approval affirms the clinical value and versatility of XELJANZ, the first and only Janus kinase (JAK) inhibitor approved for five indications in the United States for the treatment of patients with certain immuno-inflammatory conditions."
For more details, check out the full story on the link below:
FDA Approves Tofacitinib For Treatment Of Active Ankylosing Spondylitis
Dental Anxiety is highly prevalent amongst pregnant women, according to a recent study published in the International Dental Journal.
Access to oral care during pregnancy is important for the maintenance of optimal oral health. The aim of this study was to estimate dental anxiety (DA) and its association with previous dental visits and sociodemographic factors amongst pregnant women.
For more details, check out the full story on the link below:
Dental Anxiety Highly Prevalent Amongst Pregnant Women: Study
Vitiligo is a frequent depigmenting condition caused by autoimmune melanocyte loss. Some data shows that melanocytes in the auditory system are involved in the illness process. However, the link between vitiligo and sensorineural hearing loss (SNHL) is yet unknown.
A new study data to date suggests a link of sensorineural hearing loss (SNHL) with vitiligo. The findings point to the need of audiologic evaluation in the early detection and management of hearing loss in vitiligo patients.
For more details, check out the full story on the link below:
Vitiligo Patients Have Significantly Increased Odds Of Sensorineural Hearing Loss: Study
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd